this present day [30:10%: Respiratory: Nasopharyngitis (6% to 11%) 1% to 10%: Cardiovascular: Hypertension (3%) Central nervous system: Dizziness (4%), fatigue (2%) Dermatologic: Skin rash (1%) Gastrointestinal: Gastroenteritis (3% to 6%), nausea (2%) Genitourinary: Urinary tract infection (5%) Hematologic & Oncologic: Bruise (1%) Infection: Influenza (8% to 9%) Local: Injection site reaction (including erythema, pain, bruising: 6%) Neuromuscular & Skeletal: Myalgia (4%) Respiratory: Upper respiratory tract infection (9%), cough (1% to 5%), sinusitis (4%)] Drug Status Rx Availability Prescription only N/A CSA Schedule Not a controlled drug Approval History Drug history at FDA Evolocumab Rating 57 User Reviews 6.6 /10 57 User Reviews 6.6 Rate it! Drug Class PCSK9 inhibitors Related Drugs PCSK9 inhibitors Repatha , Praluent , alirocumab , Repatha Pushtronex High Cholesterol, Familial Heterozygous atorvastatin , simvastatin , Crestor , Lipitor , pravastatin , Zocor , Zetia , lovastatin , More... High Cholesterol, Familial Homozygous atorvastatin , simvastatin , Crestor , Lipitor , Zocor , rosuvastatin , Vytorin , Repatha , More... High Cholesterol atorvastatin , simvastatin , Crestor , Lipitor , Zocor , Zetia , lovastatin , niacin , More... fit
penal complex Evolocumab travelers
EmoticonEmoticon